vs
优尼威尔（DSGR）与Royalty Pharma plc（RPRX）财务数据对比。点击上方公司名可切换其他公司
Royalty Pharma plc的季度营收约是优尼威尔的1.2倍（$622.0M vs $518.0M），Royalty Pharma plc净利率更高（34.4% vs 1.2%，领先33.2%），优尼威尔同比增速更快（10.7% vs 4.8%），过去两年优尼威尔的营收复合增速更高（13.1% vs 4.6%）
优尼威尔解决方案公司是一家全球化化学品与原料分销商，同时可为客户提供各类增值服务，业务网络覆盖全球多个地区，在化工及原料分销领域拥有丰富的行业经验与资源积累。
本公司是总部位于美国马萨诸塞州剑桥市的临床阶段生物制药企业，专注于研发可调节转化生长因子β（TGF-β）超家族蛋白的药物，该类蛋白在红细胞、肌肉、骨骼、血管等细胞与组织的生长修复过程中发挥核心作用。
DSGR vs RPRX — 直观对比
营收规模更大
RPRX
是对方的1.2倍
$518.0M
营收增速更快
DSGR
高出5.9%
4.8%
净利率更高
RPRX
高出33.2%
1.2%
两年增速更快
DSGR
近两年复合增速
4.6%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $518.0M | $622.0M |
| 净利润 | $6.5M | $214.2M |
| 毛利率 | 32.9% | — |
| 营业利润率 | 4.6% | 62.4% |
| 净利率 | 1.2% | 34.4% |
| 营收同比 | 10.7% | 4.8% |
| 净利润同比 | -70.6% | 2.9% |
| 每股收益（稀释后） | $0.14 | $0.49 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DSGRRPRX
| Q4 25 | — | $622.0M | ||
| Q3 25 | $518.0M | $609.3M | ||
| Q2 25 | $502.4M | $578.7M | ||
| Q1 25 | $478.0M | $568.2M | ||
| Q4 24 | $480.5M | $593.6M | ||
| Q3 24 | $468.0M | $564.7M | ||
| Q2 24 | $439.5M | $537.3M | ||
| Q1 24 | $416.1M | $568.0M |
净利润DSGRRPRX
| Q4 25 | — | $214.2M | ||
| Q3 25 | $6.5M | $288.2M | ||
| Q2 25 | $5.0M | $30.2M | ||
| Q1 25 | $3.3M | $238.3M | ||
| Q4 24 | $-25.9M | $208.2M | ||
| Q3 24 | $21.9M | $544.0M | ||
| Q2 24 | $1.9M | $102.0M | ||
| Q1 24 | $-5.2M | $4.8M |
毛利率DSGRRPRX
| Q4 25 | — | — | ||
| Q3 25 | 32.9% | — | ||
| Q2 25 | 33.9% | — | ||
| Q1 25 | 34.3% | — | ||
| Q4 24 | 33.3% | — | ||
| Q3 24 | 33.9% | — | ||
| Q2 24 | 34.5% | — | ||
| Q1 24 | 34.5% | — |
营业利润率DSGRRPRX
| Q4 25 | — | 62.4% | ||
| Q3 25 | 4.6% | 70.1% | ||
| Q2 25 | 5.3% | 36.3% | ||
| Q1 25 | 4.2% | 94.0% | ||
| Q4 24 | 4.2% | 60.9% | ||
| Q3 24 | 4.0% | — | ||
| Q2 24 | 3.2% | 50.2% | ||
| Q1 24 | 0.7% | -13.0% |
净利率DSGRRPRX
| Q4 25 | — | 34.4% | ||
| Q3 25 | 1.2% | 47.3% | ||
| Q2 25 | 1.0% | 5.2% | ||
| Q1 25 | 0.7% | 41.9% | ||
| Q4 24 | -5.4% | 35.1% | ||
| Q3 24 | 4.7% | 96.3% | ||
| Q2 24 | 0.4% | 19.0% | ||
| Q1 24 | -1.3% | 0.8% |
每股收益（稀释后）DSGRRPRX
| Q4 25 | — | $0.49 | ||
| Q3 25 | $0.14 | $0.67 | ||
| Q2 25 | $0.11 | $0.07 | ||
| Q1 25 | $0.07 | $0.55 | ||
| Q4 24 | $-0.55 | $0.46 | ||
| Q3 24 | $0.46 | $1.21 | ||
| Q2 24 | $0.04 | $0.23 | ||
| Q1 24 | $-0.11 | $0.01 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $69.2M | $618.7M |
| 总债务越低越好 | $665.5M | $9.0B |
| 股东权益账面价值 | $653.9M | $9.7B |
| 总资产 | $1.8B | $19.6B |
| 负债/权益比越低杠杆越低 | 1.02× | 0.92× |
8季度趋势，按日历期对齐
现金及短期投资DSGRRPRX
| Q4 25 | — | $618.7M | ||
| Q3 25 | $69.2M | $938.9M | ||
| Q2 25 | $47.4M | $631.9M | ||
| Q1 25 | $65.4M | $1.1B | ||
| Q4 24 | $66.5M | $929.0M | ||
| Q3 24 | $61.3M | $950.1M | ||
| Q2 24 | $46.8M | $1.8B | ||
| Q1 24 | $73.1M | $843.0M |
总债务DSGRRPRX
| Q4 25 | — | $9.0B | ||
| Q3 25 | $665.5M | $8.9B | ||
| Q2 25 | $675.0M | $8.0B | ||
| Q1 25 | $712.4M | $7.6B | ||
| Q4 24 | $693.9M | $7.6B | ||
| Q3 24 | $704.1M | $7.6B | ||
| Q2 24 | $573.7M | $7.6B | ||
| Q1 24 | $535.7M | $6.1B |
股东权益DSGRRPRX
| Q4 25 | — | $9.7B | ||
| Q3 25 | $653.9M | $9.6B | ||
| Q2 25 | $649.4M | $9.5B | ||
| Q1 25 | $636.7M | $9.8B | ||
| Q4 24 | $640.5M | $10.3B | ||
| Q3 24 | $680.8M | $10.3B | ||
| Q2 24 | $653.3M | $9.8B | ||
| Q1 24 | $654.7M | $9.9B |
总资产DSGRRPRX
| Q4 25 | — | $19.6B | ||
| Q3 25 | $1.8B | $19.3B | ||
| Q2 25 | $1.8B | $18.3B | ||
| Q1 25 | $1.8B | $17.6B | ||
| Q4 24 | $1.7B | $18.2B | ||
| Q3 24 | $1.8B | $18.0B | ||
| Q2 24 | $1.6B | $17.7B | ||
| Q1 24 | $1.5B | $16.1B |
负债/权益比DSGRRPRX
| Q4 25 | — | 0.92× | ||
| Q3 25 | 1.02× | 0.93× | ||
| Q2 25 | 1.04× | 0.84× | ||
| Q1 25 | 1.12× | 0.78× | ||
| Q4 24 | 1.08× | 0.74× | ||
| Q3 24 | 1.03× | 0.74× | ||
| Q2 24 | 0.88× | 0.78× | ||
| Q1 24 | 0.82× | 0.62× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $38.4M | $827.1M |
| 自由现金流经营现金流 - 资本支出 | $32.9M | — |
| 自由现金流率自由现金流/营收 | 6.3% | — |
| 资本支出强度资本支出/营收 | 1.1% | — |
| 现金转化率经营现金流/净利润 | 5.95× | 3.86× |
| 过去12个月自由现金流最近4个季度 | $92.2M | — |
8季度趋势，按日历期对齐
经营现金流DSGRRPRX
| Q4 25 | — | $827.1M | ||
| Q3 25 | $38.4M | $702.6M | ||
| Q2 25 | $33.3M | $364.0M | ||
| Q1 25 | $-4.8M | $596.1M | ||
| Q4 24 | $45.7M | $742.5M | ||
| Q3 24 | $-17.3M | $703.6M | ||
| Q2 24 | $21.4M | $658.2M | ||
| Q1 24 | $6.6M | $664.6M |
自由现金流DSGRRPRX
| Q4 25 | — | — | ||
| Q3 25 | $32.9M | — | ||
| Q2 25 | $28.7M | — | ||
| Q1 25 | $-10.4M | — | ||
| Q4 24 | $41.1M | — | ||
| Q3 24 | $-20.5M | — | ||
| Q2 24 | $18.0M | — | ||
| Q1 24 | $4.2M | — |
自由现金流率DSGRRPRX
| Q4 25 | — | — | ||
| Q3 25 | 6.3% | — | ||
| Q2 25 | 5.7% | — | ||
| Q1 25 | -2.2% | — | ||
| Q4 24 | 8.6% | — | ||
| Q3 24 | -4.4% | — | ||
| Q2 24 | 4.1% | — | ||
| Q1 24 | 1.0% | — |
资本支出强度DSGRRPRX
| Q4 25 | — | — | ||
| Q3 25 | 1.1% | — | ||
| Q2 25 | 0.9% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 1.0% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.8% | — | ||
| Q1 24 | 0.6% | — |
现金转化率DSGRRPRX
| Q4 25 | — | 3.86× | ||
| Q3 25 | 5.95× | 2.44× | ||
| Q2 25 | 6.66× | 12.06× | ||
| Q1 25 | -1.46× | 2.50× | ||
| Q4 24 | — | 3.57× | ||
| Q3 24 | -0.79× | 1.29× | ||
| Q2 24 | 11.28× | 6.45× | ||
| Q1 24 | — | 139.10× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DSGR
| Test Equity Segment | $206.5M | 40% |
| Gexpro Services Segment | $130.5M | 25% |
| Lawson Segment | $121.5M | 23% |
| Canada Branch Division Segment | $60.0M | 12% |
RPRX
| Financial Royalty Assets | $592.4M | 95% |
| Royalty Income Other | $29.6M | 5% |
